# Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026
Canonical URL: https://biopharmsignal.com/news/NERV/minerva-neurosciences-to-host-virtual-kol-event-to-discuss-roluperidone-from-unmet-need-to-reality-potentially-the-first-treatment-for-patients-with-negative-symptoms-of-schizophrenia-on-february-3-2026
Ticker: NERV
Company: Minerva Neuroscience
Source: Minerva Neuroscience
Published: 2026-01-26 12:00 EST
Original Source URL: https://ir.minervaneurosciences.com
## Summary

BURLINGTON, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that it will host a virtual key opinion leader (KOL) event

## Article Body
BURLINGTON, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that it will host a virtual key opinion leader (KOL) event
## Recent Company News
- 2026-06-01 20:05 EST — [Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs](https://biopharmsignal.com/news/NERV/minerva-neurosciences-establishes-scientific-advisory-board-to-advance-development-of-roluperidone-and-future-pipeline-programs) — Source: Minerva Neuroscience
- 2026-05-18 20:05 EST — [Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/NERV/minerva-neurosciences-to-participate-in-the-2026-jefferies-global-healthcare-conference) — Source: Minerva Neuroscience
- 2026-05-05 12:00 EST — [Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates](https://biopharmsignal.com/news/NERV/minerva-neurosciences-provides-first-quarter-2026-financial-results-and-business-updates) — Source: Minerva Neuroscience
- 2026-04-02 20:05 EST — [Minerva Announces Leadership Transition](https://biopharmsignal.com/news/NERV/minerva-announces-leadership-transition) — Source: Minerva Neuroscience
- 2026-03-31 20:05 EST — [Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia](https://biopharmsignal.com/news/NERV/minerva-neurosciences-announces-first-patient-screened-in-global-phase-3-confirmatory-trial-of-roluperidone-for-the-treatment-of-negative-symptoms-of-schizophrenia) — Source: Minerva Neuroscience
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)